AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12118868 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-display mapping with vertical and depth dimensions coupled to up-down and fore-aft control axes
Number of subjects: 16
Study 12118868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking along the depth dimension
Number of subjects: 16
Study 12118868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking along the up-down axis of the hand controller
Number of subjects: 16
Study 10450339 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam treatment for 10 days
Number of subjects: 6
Study 10450339 — intervention group
Group type: COMPARATOR
Intervention: Compressed gas (atmospheric air)
Number of subjects: 6
Study 7799087 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 24
Study 2135706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30-60 mg orally 2 hours prior to ECT
Number of subjects: 8
Study 2135706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31163978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 27935
Study 31163978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily alone
Number of subjects: 27935
Study 31163978 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg alone
Number of subjects: 27935
Study 31163978 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin
Number of subjects: 27935
Study 31163978 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 27935
Study 29983376 — intervention group
Group type: EXPERIMENTAL
Intervention: YESHealth intervention
Number of subjects: 0
Study 29983376 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27626518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 209
Study 27626518 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy without rituximab)
Number of subjects: 209
Study 24493237 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH Forgiveness intervention
Number of subjects: 102
Study 24493237 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 102
Study 21450591 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE group (35 subjects)
Number of subjects: 71
Study 21450591 — intervention group
Group type: COMPARATOR
Intervention: AeT group (36 subjects)
Number of subjects: 71
Study 21450591 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage heart rate reserve and peak workload methods
Number of subjects: 71
Study 20386260 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPS plus an adjunctive individual therapy
Number of subjects: 79
Study 20386260 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 79
Study 18353631 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with chemotherapy
Number of subjects: 95
Study 18353631 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy without chemotherapy
Number of subjects: 95
Study 15994714 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (tobacco use treatment delivered by mental health providers)
Number of subjects: 66
Study 15994714 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care (cessation treatment delivered separately by smoking‐cessation specialists)
Number of subjects: 66
Study 12623832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol combination
Number of subjects: 293
Study 12623832 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine + timolol
Number of subjects: 293
Study 10100063 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day)
Number of subjects: 3506
Study 10100063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3506
Study 8904620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 166
Study 8904620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 166
Study 8904620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 166
Study 8904620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 1725033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day (treatment A)
Number of subjects: 16
Study 1725033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 1.25 mg/day (treatment B)
Number of subjects: 16
Study 6350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal aspirin (ASA) 22.5 mg per deciliter
Number of subjects: 0
Study 6350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal aspirin (ASA)
Number of subjects: 0
Study 6350409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ASA, Na salicylate, and indomethacin
Number of subjects: 0
Study 6350409 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31448718 — intervention group
Group type: EXPERIMENTAL
Intervention: BRP varnish 2.5%
Number of subjects: 24
Study 31329961 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute mindfulness strategy
Number of subjects: 60
Study 31329961 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (education on the Gate Control Theory of Pain)
Number of subjects: 60
Study 28611080 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-assessed inflammation
Number of subjects: 210
Study 28611080 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-assessed synovitis
Number of subjects: 210
Study 28611080 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-assessed synovitis and tenosynovitis mean scores
Number of subjects: 210
Study 27756209 — intervention group
Group type: EXPERIMENTAL
Intervention: mDOT (mobile directly observed therapy) with fixed dose hydroxyurea (HU) therapy and standard monitoring
Number of subjects: 100
Study 27756209 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (SM) with fixed dose hydroxyurea (HU) therapy
Number of subjects: 100
Study 25144885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic abduction brace with Mitchell shoes
Number of subjects: 30
Study 25144885 — intervention group
Group type: COMPARATOR
Intervention: Static abduction bar with Mitchell shoes
Number of subjects: 30
Study 23176668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Psychological Intervention (CPI)
Number of subjects: 140
Study 19887533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed tracheal tubes (Microcuff PET)
Number of subjects: 2246
Study 19887533 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed tracheal tubes (Mallinckrodt, Portex, Rüsch, Sheridan)
Number of subjects: 2246
Study 17485707 — intervention group
Group type: COMPARATOR
Intervention: Single autologous stem-cell transplantation (ASCT) with high-dose melphalan at 200 mg/m2 (arm A)
Number of subjects: 321
Study 17485707 — intervention group
Group type: EXPERIMENTAL
Intervention: Double autologous stem-cell transplantation (ASCT) with melphalan at 200 mg/m2 followed by melphalan at 120 mg/m2 and busulfan at 12 mg/kg (arm B)
Number of subjects: 321
Study 17485707 — intervention group
Group type: COMPARATOR
Intervention: Single ASCT (arm A)
Number of subjects: 321
Study 17485707 — intervention group
Group type: EXPERIMENTAL
Intervention: Double ASCT (arm B)
Number of subjects: 321
Study 17485707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for the whole group (both arms)
Number of subjects: 321
Study 15172088 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (CE), 0.625 mg, and medroxyprogesterone acetate (MPA), 5 mg
Number of subjects: 62
Study 15172088 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2), 2 mg, and norethisterone acetate (NETA), 1 mg
Number of subjects: 62
Study 12138526 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for STD recurrence
Number of subjects: 0
Study 9485125 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 44
Study 9485125 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 44
Study 9485125 — intervention group
Group type: COMPARATOR
Intervention: Left lateral decubitus position
Number of subjects: 44
Study 7911402 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 434 (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Number of subjects: 131
Study 7911402 — intervention group
Group type: COMPARATOR
Intervention: CTM-D (chlorpheniramine maleate 12 mg and pseudoephedrine sulfate 120 mg)
Number of subjects: 131
Study 7911402 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 434
Number of subjects: 131
Study 2679230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 12
Study 2679230 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 12
Study 2679230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 12
Study 29526471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (nHF) therapy
Number of subjects: 278
Study 29526471 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 278
Study 28198590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 40 mg
Number of subjects: 64
Study 28198590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 120 mg
Number of subjects: 64
Study 28198590 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 64
Study 28198590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 26238412 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 912
Study 26238412 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) exposure in vitro
Number of subjects: 912
Study 26238412 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxytamoxifen (4-OHT) exposure in vitro
Number of subjects: 912
Study 26238412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear HER4 protein expression
Number of subjects: 912
Study 26238412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoplasmic HER4 protein expression
Number of subjects: 912
Study 24683779 — intervention group
Group type: EXPERIMENTAL
Intervention: OFL: Phosphoric Acid/Optibond FL/Premise Flow
Number of subjects: 50
Study 24683779 — intervention group
Group type: EXPERIMENTAL
Intervention: OAO: Optibond All‐In‐One/Premise Flowable
Number of subjects: 50
Study 24683779 — intervention group
Group type: COMPARATOR
Intervention: II: Polyacrylic Acid/Fuji II
Number of subjects: 50
Study 24683779 — intervention group
Group type: COMPARATOR
Intervention: IX: Polyacrylic Acid/Fuji IX
Number of subjects: 50
Study 24683779 — intervention group
Group type: COMPARATOR
Intervention: V: Vertise Flow
Number of subjects: 50
Study 21879624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling with a focus on verbal interactions
Number of subjects: 42
Study 21879624 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived verbal interactions
Number of subjects: 42
Study 18494345 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK with mitomycin C (MMC) 0.02% applied for 1 minute
Number of subjects: 228
Study 18494345 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 228
Study 18494345 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK with MMC
Number of subjects: 228
Study 18494345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LASEK and LASIK
Number of subjects: 228
Study 16096441 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide with albumin
Number of subjects: 40
Study 16096441 — intervention group
Group type: COMPARATOR
Intervention: Furosemide with placebo (control)
Number of subjects: 40
Study 12027149 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training with elastic bands, 3 sessions a week for 4 months.
Number of subjects: 10
Study 12027149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 10
Study 12027149 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training with elastic bands.
Number of subjects: 10
Study 10079459 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Psychological Treatment (SPT)
Number of subjects: 33
Study 10079459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation Treatment (COT)
Number of subjects: 33
Study 10079459 — intervention group
Group type: COMPARATOR
Intervention: Control/Nutritional Counseling (C/NC)
Number of subjects: 33
Study 8616479 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 62
Study 8616479 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 62
Study 2285635 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg piretanide bid
Number of subjects: 46
Study 2285635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7137070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (300 mg daily)
Number of subjects: 22
Study 7137070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31328230 — intervention group
Group type: EXPERIMENTAL
Intervention: BERN scoring criteria for microsleep episodes (MSEs)
Number of subjects: 76
Study 31328230 — intervention group
Group type: COMPARATOR
Intervention: AASM scoring criteria for microsleep episodes (MSEs)
Number of subjects: 76
Study 31328230 — intervention group
Group type: EXPERIMENTAL
Intervention: BERN scoring criteria
Number of subjects: 76
Study 31123992 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 48
Study 31123992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28729473 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen titration
Number of subjects: 187
Study 28729473 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 187
Study 26190286 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 26190286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 26190286 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 23415416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid management guided by bioimpedance spectroscopy
Number of subjects: 156
Study 23415416 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (Control)
Number of subjects: 156
Study 21243500 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 17
Study 21243500 — intervention group
Group type: EXPERIMENTAL
Intervention: inulin/VSL#3
Number of subjects: 17
Study 21243500 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac/inulin/VSL#3
Number of subjects: 17
Study 21243500 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 17
Study 19812399 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 898
Study 19812399 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 898
Study 17762816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear avoidance beliefs (FAB)
Number of subjects: 661
Study 17762816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain (LBP)
Number of subjects: 661
Study 15125213 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids combined with thyroxine
Number of subjects: 60
Study 15125213 — intervention group
Group type: COMPARATOR
Intervention: Steroids only
Number of subjects: 60
Study 12207869 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbatrol (2 x 200 mg capsules), b.i.d. for 5 days
Number of subjects: 15
Study 12207869 — intervention group
Group type: COMPARATOR
Intervention: Tegretol‐XR (400 mg), b.i.d. for 5 days
Number of subjects: 15
Study 9427920 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus iontophoresis of calcitonin gene‐related peptide and vasoactive intestinal polypeptide
Number of subjects: 66
Study 9427920 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plus placebo iontophoresis
Number of subjects: 66
Study 8085219 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated toothpicks (0.80 mg F as NaF)
Number of subjects: 10
Study 8085219 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg F tablet (Fludent)
Number of subjects: 10
Study 3140631 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 60
Study 3140631 — intervention group
Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 60
Study 31559483 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of medical therapy with sacubitril/valsartan, ivabradine, or both after CRT implantation
Number of subjects: 182
Study 31559483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 182
Study 31559483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 182
Study 31559483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sacubitril/valsartan and ivabradine
Number of subjects: 182
Study 31559483 — intervention group
Group type: COMPARATOR
Intervention: No indication at baseline
Number of subjects: 182
Study 31212058 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory intermittent TBS (iTBS)
Number of subjects: 60
Study 31212058 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory continuous TBS (cTBS)
Number of subjects: 60
Study 31212058 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 29231603 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-needling moxibustion treatment for KOA, 40 min per treatment, 12 treatments over 3 weeks.
Number of subjects: 50
Study 29231603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 3 weeks).
Number of subjects: 50
Study 29231603 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-needling moxibustion treatment for KOA.
Number of subjects: 50
Study 25957107 — intervention group
Group type: EXPERIMENTAL
Intervention: Taikong Yangxin (Chinese herbal medicine)
Number of subjects: 14
Study 25957107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 23677418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ascorbic acid (250 mg tablets vaginally at bedtime once a day for 6 days, followed by one tablet per week for 12 weeks)
Number of subjects: 140
Study 23677418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ascorbic acid
Number of subjects: 140
Study 23677418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study 22260015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushenhuoxue Granules
Number of subjects: 120
Study 22260015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19150703 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 10 microg/kg per day subcutaneously for 5 days
Number of subjects: 280
Study 19150703 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 280
Study 16283258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch (35 mg)
Number of subjects: 169
Study 16283258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 15520032 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched vocabulary consultations
Number of subjects: 62
Study 15520032 — intervention group
Group type: COMPARATOR
Intervention: Unmatched vocabulary consultations
Number of subjects: 62
Study 11200381 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (ACA) for 5 days
Number of subjects: 433
Study 11200381 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (ACA) for 10 days
Number of subjects: 433
Study 11200381 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (ACA) for 5 days and 10 days
Number of subjects: 433
Study 9311208 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol-fentanyl-ketamine (PFK)
Number of subjects: 12
Study 9311208 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-nitrous oxide anesthesia (GOI)
Number of subjects: 12
Study 8357556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 36
Study 8357556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and interferon-alpha (IFN-alpha)
Number of subjects: 36
Study 3596768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25‐50 mg b.i.d.)
Number of subjects: 18
Study 3596768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120‐180 mg b.i.d.)
Number of subjects: 18
Study 3596768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31236782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential compression devices (SCDs) applied to the arm harboring the PICC
Number of subjects: 77
Study 31236782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCD applied)
Number of subjects: 77
Study 31236782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential compression devices (SCDs) applied to the arm harboring the PICC (after accounting for crossovers)
Number of subjects: 77
Study 31236782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCD applied, after accounting for crossovers)
Number of subjects: 77
Study 31236782 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (symptomatic UE DVT and pulmonary embolism observed in patients not wearing SCD)
Number of subjects: 77
Study 30702019 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine dosed 24-48 mg/day
Number of subjects: 0
Study 30702019 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 0
Study 30702019 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term open-label study of deutetrabenazine
Number of subjects: 0
Study 28489298 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT plus cetirizine 10 mg (n=10)
Number of subjects: 20
Study 28489298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 20